{"id":"W2101922439","doi":"10.1016/s1470-2045(14)70379-1","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":1019,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck KGaA","keywords":"Temozolomide; Medicine; Chemoradiotherapy; Internal medicine; Oncology; Clinical endpoint; Phases of clinical research; Progression-free survival; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04591526199650049,"score_gpt":0.3746563513188675,"score_spread":0.3287410893223671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}